FDA-Cleared Gentamicin 0.016-256 MTS™
Liofilc
hem has received clearance from the FDA to market in the United States the Gentamicin 0.016-256 MTS™ (MIC Test Strip), a quantitative assay for determining the Minimum Inhibitory Concentration (MIC) of Gentamicin.
Gentamicin MTS™ has been shown to be active both clinically and in vitro against the following Gram-negative bacteria:
Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens.